Increasing the effectiveness of oxaliplatin using colloidal immunoglobulin G nanoparticles: Synthesis, cytotoxicity, interaction, and release studies.

A novel biomacromolecule was prepared for a stabilizer sustained anticancer drug release system. Colloidal immunoglobulin G (IgG) nanoparticles (IgGNP) were synthesized and then characterized using FT-IR, SEM, zeta sizer, and AFM. Moreover, the formation of spherical shape IgGNP with an appropriate average size (144.56 ± 2 nm) and a narrow distribution for the drug release was confirmed. Also, the conjugation of oxaliplatin (OX) to IgGNP (OX@IgGNP) was demonstrated via the combination of spectroscopy and physical analyses. In this regard, the interaction was spantaneous with static quenching mechanism. OX caused well dispersity with no agglomeration on IgGNP with an average size of 142.31 ± 4 nm. Furthermore, the encapsulation efficiency (%EE) and drug loading (%DL) percentages were determined. Accordingly, the release behavior indicated that OX was sustained from IgGNP more than IgG (approximately 150 h) and the highest release amount of OX (100 %) was obtained at acidic medium (pH 5.5). Notably, the kinetic model was zero order and release mechanism followed by diffusion and Fick's model at neutral medium and combination of diffusion and swelling controlled and non-Fickian model at acidic medium. In addition, the anticancer effect of OX@IgGNP was evaluated on the human breast cancer cell lines, MCF-7 using MTT assay and DAPI staining that showed a remarkable efficacy, while the cytotoxicity in human fibroblast cell lines, HFFF2 has decreased. In this study, gene expression was investigated using real time PCR, which verified IgGNP induced programmed cell death in MCF-7 breast cancer cell more effectively than free OX. Subsequently, a novel nano scale biological macromolecule can be introduced as a sustained and prolonged anticancer drug release.